Related references
Note: Only part of the references are listed.Chromogenic in-situ hybridization:: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm
WM Hanna et al.
MODERN PATHOLOGY (2006)
Meeting highlights:: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
A Goldhirsch et al.
ANNALS OF ONCOLOGY (2005)
Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab
N Dybdal et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization - A single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring
P Lal et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2004)
Updated recommendations for HER2 testing in the UK
IO Ellis et al.
JOURNAL OF CLINICAL PATHOLOGY (2004)
Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization
L Hammock et al.
HUMAN PATHOLOGY (2003)
The clinical evaluation of HER-2 status: which test to use?
J Bartlett et al.
JOURNAL OF PATHOLOGY (2003)
Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres
M Dowsett et al.
JOURNAL OF PATHOLOGY (2003)
Share Paper
